The clinical effect of pulmonary surfactant in treatment of preterm children respiratory distress syndrome / 中国基层医药

ABSTRACT

Objective To discuss the clinical effect of pulmonary surfactant in the treatment of preterm children respiratory distress syndrome (RDS).Methods 86 RDS premature children were randomly divided into two groups by digital number table methods,43 cases were in each group,the control group was given nasal continuous positive airway pressure (NCPAP) treatment,while the observation group was given intratracheal instillation PS on the basis of the control group.The arterial blood gases,outcome indicators of changes in circumstances were compared between the two groups.Results After treatment,the PaO2 and PaO2/FiO2 of the observation group were (67.10 ±3.88) mmHg and (191.30 ± 10.72) higher than (43.81 ± 3.78) mmHg and (81.71 ± 5.34) of pre-treatment and (53.35 ± 3.86) mmHg and (126.88 ± 8.50) of the control group (t =9.35,9.50,7.34,7.20,all P ＜ 0.05) ; while PaCO2 was (37.38 ± 3.65) mmHg significantly lower than (59.15 ± 4.27) mmHg of pre-treatment and (58.76 ±3.86) mmHg of the control group,the differences were statistically significance (t =10.15,7.62,all P ＜0.05);after treatment,the IVH and ROP incidence of the observation group were 4.65％ and 6.98％,which were significantly lower than 13.95％ and 16.28％ of the control group (x2 =7.68,7.39,all P ＜ 0.05) ; while the two groups showed no significant difference in incidence of BPD (P ＞ 0.05).Conclusion Pulmonary surfactant in the treatment of respiratory distress syndrome in premature children has significant effect,and it can improve lung function in children with disease outcome and prognosis.